An ESR1 mutation locks the estrogen receptor in a permanently "on" state, independent of estrogen. This renders aromatase inhibitors (AIs) ineffective but means therapies that degrade the receptor itself, like SERDs, can still be effective treatment options.
Retrospective analysis of the BOLERO-2 trial revealed that the mTOR inhibitor everolimus benefits patients irrespective of their PI3K mutation status. This challenges the assumption that pathway-targeted therapies are only effective when a specific mutation is present, suggesting broader mechanisms of action.
While liquid biopsies (ctDNA) excel at detecting mutations, tissue biopsies are irreplaceable for assessing the fundamental biology of the most life-threatening metastatic sites. For instance, a direct liver biopsy is needed to confirm estrogen receptor expression, a critical factor that ctDNA cannot determine.
When patients present with both ESR1 and PI3K mutations, treatment selection isn't based on a definitive molecular test. Instead, oncologists make a clinical judgment, inferring the dominant resistance pathway from factors like the duration of prior therapy to guide their choice of targeted agent.
Despite strong efficacy data for IV-based regimens like gadatilisib, their adoption faces significant practical hurdles. For a patient population accustomed to long-term oral therapies, the logistical burden of weekly clinic infusions may limit real-world use, particularly for patients in rural areas.
Clinicians are pragmatically using novel drug combinations based on safety and early efficacy data from Phase 1b/2 trials like ELEVATE. This practice circumvents the impossibility of running Phase 3 trials for every permutation and is reportedly being covered by insurers, accelerating patient access to new options.